Detection of lipoarabinomannan in urine and serum of HIV-positive and HIV-negative TB suspects using an improved capture-enzyme linked immuno absorbent assay and gas chromatography/mass spectrometry

TB diagnosis and treatment monitoring in resource limited regions rely heavily on serial sputum smear microscopy and bacterial culture. These microbiological methods are time-consuming, expensive and lack adequate sensitivity. The WHO states that improved TB diagnosis and treatment is imperative to achieve an end to the TB epidemic by 2030. Commercially available lipoarabinomannan (LAM) detection tools perform at low sensitivity that are highly dependent on the underlying immunological status of the patient; those with advanced HIV infection perform well.

Source: Tuberculosis - June 6, 2018 Category: Respiratory Medicine Authors: Anita G. Amin, Prithwiraj De, John S. Spencer, Patrick J. Brennan, Joshua Daum, Barbara G. Andre, Maju Joe, Yu Bai, Lars Laurentius, Marc D. Porter, William J. Honnen, Alok Choudhary, Todd L. Lowary, Abraham Pinter, Delphi Chatterjee Source Type: research